News

Novartis considers filing Arzerra for relapsed CLL on strong data


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Novartis considers filing Arzerra for relapsed CLL on strong data

 

Date: 15/06/2015

Novartis is evaluating a potential regulatory filing for Arzerra in relapsed chronic lymphocytic leukaemia after the drug was shown to significantly increase progression-free survival in a Phase III trial.

Data from the COMPLEMENT 2 study show that a combination of Arzerra (ofatumumab), fludarabine and cyclophosphamide boosted progression-free survival by 54% compared to therapy with the latter two drugs alone (28.9 months versus 18.8 months, respectively).

For more click here

Source: Pharma Times

© Catalyst Innovation Portal 2019